drugset / Trial / NCT02226757
Paclitaxel-trastuzumab in EGFR-mutated NSCLC Patients
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This study is a pilot study in EGFR-mutated NSCLC patients who have progressed on standard-dose TKIs. Tumor biopsies will be evaluated for HER2-expression. In case of HER2 expression, patients can participate in the trial after obtaining informed consent. Patients will be treated with weekly paclitaxel-trastuzumab.
Timeline
- Start
- 2014-08
- Primary completion
- 2016-08
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Paclitaxel | Small molecule | 60 mg/m2 | Intravenous |
| Subject | Trastuzumab | Monoclonal antibody | 2 mg/kg | Intravenous |